81 - Late Breaking Vaccine Studies

Moderator(s)

• 

  Kathleen Neuzil, MD

  Professor
  Medicine / CVD
  University of Maryland School of Medicine Center for Vaccine Development and Global Health
  Baltimore, MD, United States

  I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Meagan Deming, MD, PHD

  Assistant Professor
  Center for Vaccine Development, University of Maryland Medical Center
  Baltimore, MD, United States

  I do not have any relevant financial / non-financial relationships with any proprietary interests.

No CE Credit Offered

Presentations:

• 1:45 PM – 1:57 PM US ET

  Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
  

  Presenting Author: Michael G. Ison, MD MS – Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

  Co-Author: Alberto Papi, MD – University of Ferrara, St. Anna University Hospital, Ferrara, Italy

  Co-Author: Joanne M. Langley, MD – Dalhousie University, IWK Health and Nova Scotia Health, Halifax, Canada

  Co-Author: Dong-Gun Lee, PhD MD – The Catholic University of Korea, Seoul, South Korea

  Co-Author: Isabel Leroux-Roels, PhD MD – Ghent University and Ghent University Hospital, Ghent, Belgium

  Co-Author: Federico Martinon-Torres, MD, PhD, Assoc. Prof – Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

  Co-Author: Tino F. Schwarz, Prof. Dr. MD – Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany

  Co-Author: Richard N. Van Zyl-Smit, PhD MD – University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa

  Co-Author: Nancy Dezutter, PhD, PharmD – GSK, Wavre, Belgium

  Co-Author: Nathalie De Schrevel, PhD – GSK, Rixensart, Belgium

  Co-Author: Laurence Fissette, Master in Statistics – GSK, Wavre, Belgium

  Co-Author: Marie-Pierre David, Master in Statistics – GSK, Wavre, Belgium

  Co-Author: Marie Van Der Wielen, MD – GSK, Wavre, Belgium

  Co-Author: Lusine Kostanyan, MD – GSK, Wavre, Belgium

  Co-Author: Veronica Hulstrøm, PhD MD – GSK, Wavre, Belgium
• 1:57 PM – 2:09 PM US ET

  Safety and Immunogenicity of a Booster Dose of Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) in Adults from the PREVENT-19 Trial in the United States
  

  Presenting Author: Germán Áñez, MD – Novavax, Inc.

  Co-Author: Lisa M. Dunkle, MD – Novavax, Inc.

  Co-Author: Cynthia L. Gay, MD, MPH – UNC-Chapel Hill

  Co-Author: Karen L. Kotloff, MD – University of Maryland School of Medicine

  Co-Author: Nita Patel, MS, CRP – Novavax, Inc.

  Co-Author: Joyce S. Plested, PhD – Novavax, Inc.

  Co-Author: Alice McGarry, MPH – Novavax, Inc.

  Co-Author: Wayne Woo, MS – Novavax, Inc.

  Co-Author: Rongman Cai, PhD – Novavax, Inc.

  Co-Author: Iksung Cho, MS – Novavax, Inc.
• 2:09 PM – 2:21 PM US ET

  Immune Responses of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in an RSV Human Challenge Trial (HCT) in Healthy Adult Participants
  

  Co-Author: Darja Schmidt, PhD – Bavarian Nordic

  Co-Author: Günter Silbernagl, MSc – Bavarian Nordic

  Presenting Author: Elke Jordan, PhD (she/her/hers) – Bavarian Nordic

  Co-Author: Victoria A. JENKINS, PhD MBA – Bavarian Nordic

  Co-Author: Stephanie Schultz, Dipl Biol – Bavarian Nordic

  Co-Author: Heinz Weidenthaler, Dr med – Bavarian Nordic
• 2:21 PM – 2:33 PM US ET

  Efficacy And Safety Of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Older Adults
  

  Presenting Author: Edward E. Walsh, MD (he/him/his) – University of Rochester

  Co-Author: Fernando Polack, MD – Fundacion INFANT

  Co-Author: Agnieszka Zareba, MD PhD – Pfizer

  Co-Author: Ann R. Falsey, MD – University of Rochester School of Medicine

  Co-Author: Gonzalo Perez Marc, MD – i-trials

  Co-Author: Qin Jiang, PhD – Pfizer

  Co-Author: Kathy Schneider, PhD – Pfizer

  Co-Author: David Cooper, PhD – Pfizer

  Co-Author: Maria Maddalena Lino, PhD – Pfizer

  Co-Author: Annaliesa S. Anderson, PhD – Pfizer

  Co-Author: Katherin U Jensen, PhD – Pfizer

  Co-Author: Kena A. Swanson, Ph.D. – Pfizer

  Co-Author: Alejandra C. Gurtman, M.D. – Pfizer

  Co-Author: William C. Gruber, MD – Pfizer

  Co-Author: Beate Schmoele-Thoma, MD – Pfizer
• 2:33 PM – 2:45 PM US ET

  High HBsAb Seroprotection Achieved 4 Weeks after 3 doses of HepB-CpG Vaccine in People Living with HIV (PLWH) without Prior HBV Vaccination (ACTG A5379 Group B Preliminary Results)
  

  Co-Author: Kristen Marks, MD, MS – Weill Cornell Medicine

  Co-Author: Minhee Kang, PhD – Harvard T.H. Chan School of Public Health

  Co-Author: Triin Umbleja, MSc – Harvard T. H. Chan School of Public Health

  Co-Author: Anchalee Avihingsanon, MD,PhD – HIV-NAT, Thai Red Cross AIDS Research Centre

  Co-Author: Patcharaphan Sugandhavesa, MD. – Research Institute for Health Sciences, Chiang Mai University

  Co-Author: Andrea L. Cox, M.D. Ph.D. – Johns Hopkins University

  Co-Author: Hugo Perazzo, MD, PhD – FIOCRUZ

  Co-Author: Jennifer C. Price, MD, PhD – University of California, San Francisco

  Co-Author: Christina Vernon, MPH – DLH Corporation

  Co-Author: Stephanie Caruso, MBA – Frontier Science

  Co-Author: Lillian Collins, MPH – Frontier Science Foundation

  Co-Author: Shawn Chiambah, PhD, RPh – NIAID, NIH

  Co-Author: Francoise Giguel, BA – Massachusetts General Hospital

  Co-Author: Michael A. Leonard, B.S., M.L.I – Vanderbilt University Medical Center

  Co-Author: jan Kosmyna, MIS, B. Ed, RN – Case Western Reserve University

  Co-Author: Allegra Cermak, MFA – AIDS Clinical Trials Group

  Co-Author: Kevin Knowles, Ph.D. – Frontier Science Foundation

  Co-Author: Philip Marzinek, B. S – Frontier Science Foundation

  Co-Author: Ceora Beijer, B.S. – UCLA Laboratory Center

  Co-Author: Sara Zabih, MS – UCLA Laboratory Center

  Co-Author: Kelvin McKoy, M.D., M.B.A. – Dynavax

  Co-Author: Beverly Alston-Smith, MD – NIAID/NIH

  Presenting Author: Kenneth E. Sherman, MD, PhD (he/him/his) – Univ. of Cincinnati College of Medicine
• 2:45 PM – 2:57 PM US ET

  Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
  

  Presenting Author: Spyros Chalkias, MD (he/him/his) – Moderna, Inc.

  Co-Author: Charles Harper, M.D. – Meridian Clinical Research

  Co-Author: Keith Vrbicky, M.D. – Meridian Clinical Research

  Co-Author: Stephen R. Walsh, MD – Brigham and Women's Hospital, Boston

  Co-Author: Brandon Essink, M.D. – Meridian Clinical Research

  Co-Author: Adam Brosz, M.D. – Meridian Clinical Research

  Co-Author: Nichole McGhee, B.S. – Moderna, Inc.

  Co-Author: Joanne Tomassini, Ph.D. – Moderna, Inc.

  Co-Author: Xing Chen, Sc.D. – Moderna, Inc.

  Co-Author: Ying Chang, M.S. – Moderna, Inc.

  Co-Author: Andrea Sutherland, M.D., MPH – Moderna, Inc.

  Co-Author: David Montefiori, Ph.D. – Department of Surgery and Duke Human Vaccine Institute

  Co-Author: Bethany Girard, Ph.D. – Moderna, Inc.

  Co-Author: Darin Edwards, Ph.D. – Moderna, Inc.

  Co-Author: Jing Feng, M.S. – Moderna, Inc.

  Co-Author: Honghong Zhou, Ph.D. – Moderna, Inc.

  Co-Author: Lindsey R. Baden, MD – Brigham and Women's Hospital

  Co-Author: Jacqueline Miller, MD – Moderna, Inc.

  Co-Author: Rituparna Das, M.D. – Moderna, Inc.